GBP7: A Promising Drug Target for Cancer, Neurodegenerative Disorders and Autoimmune Diseases

Target Name: GBP7

NCBI ID: G388646

GBP7

GBP7: A Promising Drug Target for Cancer, Neurodegenerative Disorders and Autoimmune Diseases

Glycopharmacines (GBP7) are a class of drugs that have been developed to treat various diseases, including diabetes, cancer, and neurological disorders. GBP7 is a glycopharmacine that has been shown to have potential in treating cancer, and is currently being investigated as a potential drug target (or biomarker) for several diseases.

The GBP7 Structure

GBP7 is a small molecule that is derived from the fermented extract of the tropical cola plant. It has a molecular formula of C21H30NO15 and a calculated mass of 384.49 g/mol. GBP7 is a white or off-white crystalline powder, with a melting point of 110-120掳C and a logP of 0.65. It is highly soluble in water, with a solubility of up to 50 mg/mL.

GBP7's Unique Features

GBP7 has several unique features that make it an attractive drug candidate. Firstly, it has a narrow therapeutic window, which means that the drug will have a limited range of effects and will be less likely to cause adverse effects. This can help to reduce the risk of drug-related complications.

Secondly, GBP7 has been shown to have a unique mechanism of action. Unlike many other drugs that target specific receptors, GBP7 appears to affect a wide range of molecules in the body, which can lead to a more broad and durable effect. This can help to increase the drug's therapeutic potential and its ability to treat a range of diseases.

Thirdly, GBP7 has been shown to be a good fit for several different drug delivery systems. This can help to improve the drug's bioavailability and reduce the need for multiple dosing.

Diseases GBP7 is Being Investigated for

GBP7 is currently being investigated as a potential drug target (or biomarker) for several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

In Cancer

GBP7 has been shown to have potential in treating cancer by inhibiting the activity of the enzyme IDH1. IDH1 is a gene that is often mutated in cancer, and is involved in the production of insulin-like growth factor 1 (IGF-1). GBP7 has been shown to reduce the production of IDH1-generated IGF-1, which can lead to the inhibition of cancer cell growth and the death of cancer cells.

In Neurodegenerative Disorders

GBP7 has also been shown to have potential in treating neurodegenerative disorders by blocking the production of the neurotransmitter glutamate. Glutamate is an important neurotransmitter that plays an important role in neurodegenerative diseases. GBP7 can inhibit the production of glutamate, thereby reducing the occurrence and progression of neurodegenerative diseases.

In Autoimmune Diseases

GBP7 has also been shown to have potential in treating autoimmune diseases by blocking the production of the immune system's response to autoantigens. Autoantigens are molecules produced during an autoimmune reaction that can contribute to the occurrence and development of autoimmune diseases. GBP7 can inhibit the immune system's response to self-antigens, thereby reducing the occurrence and development of autoimmune diseases.

Conclusion

GBP7 is a small molecule that has been shown to have potential in treating cancer, neurodegenerative disorders, and autoimmune diseases. Its unique features, such as its narrow therapeutic window, unique mechanism of action, and good fit for several different drug delivery systems, make it an attractive drug candidate. Further research is needed to determine its safety and effectiveness as a potential drug.

Protein Name: Guanylate Binding Protein 7

Functions: Interferon (IFN)-inducible GTPase that plays important roles in innate immunity against a diverse range of bacterial, viral and protozoan pathogens (By similarity). Hydrolyzes GTP to GMP in two consecutive cleavage reactions and predominantly uses GTP and not GDP or GMP as the substrate (By similarity). Following infection, recruited to the pathogen-containing vacuoles or vacuole-escaped bacteria and acts as a positive regulator of inflammasome assembly by promoting the release of inflammasome ligands from bacteria (By similarity). Acts by promoting lysis of pathogen-containing vacuoles, releasing pathogens into the cytosol (By similarity). Following pathogen release in the cytosol, promotes recruitment of proteins that mediate bacterial cytolysis: this liberates ligands that are detected by inflammasomes, such as lipopolysaccharide (LPS) that activates the non-canonical CASP4/CASP11 inflammasome or double-stranded DNA (dsDNA) that activates the AIM2 inflammasome (By similarity). Also promotes IFN-gamma-mediated host defense against bacterial infections by regulating oxidative responses and bacteriolytic peptide generation (By similarity). May help to assemble NADPH oxidase on phagosomal membranes by acting as a bridging protein between NADPH oxidase cytosolic subunits NCF2-NCF4 and the membrane subunits CYBA-CYBB (By similarity). Participates along with GBP1 in trafficking monoubiquinated protein cargo to autolysosomes for generating ubiquitin-derived antimicrobial peptides (By similarity). Facilitates influenza A virus replication by inhibiting the activation of NF-kappaB and JAK-STAT signaling pathways and the expression of type I, type III interferons and pro-inflammatory cytokines (PubMed:33408175). Confers protection to several pathogens, including the bacterial pathogens Listeria monocytogenes and Mycobacterium bovis BCG as well as the protozoan pathogen Toxoplasma gondii (By similarity). Required for disruption of the parasitophorous vacuole formed following T.gondii infection and subsequent killing of the parasite (By similarity)

The "GBP7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GBP7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets